Rocket Pharma Q1 net loss $61.3M; cash $318.2M; pipeline on track

ROCKET PHARMACEUTICALS, INC.

2025-Q1 EPS reported -$0.56

Net loss of $61.3M ($0.56/share) vs $62.1M in Q1 2024; R&D expenses down to $35.9M.
Cash, equivalents, investments $318.2M; operational runway into Q4 2026.
Phase 2 RP-A501 for Danon disease ongoing; program update mid-2025, data mid-2026.
Initial Phase 1 data for RP-A601 (PKP2-ACM) expected May 2025; IND for BAG3-DCM mid-2025.
Rolling BLA for RP-L102 (Fanconi Anemia); final module late 2025/early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.